If you have been reading about Dual agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-05. Numbers and descriptions here follow the published literature rather than marketing material.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Hummingbirds resemble sunbirds. The former live in the Americas and belong to an order or superorder including the swifts, while the latter live in Africa and Asia and are a family in the order Passeriformes. Also the nectar-feeding Hawaiian honeycreepers resemble the two and differs from other honeycreeper. Flightlessness has evolved in many different birds independently. However, taking this to a greater extreme, the terror birds, Gastornithiformes and dromornithids (ironically all extinct) all evolved the similar body shape (flightlessness, long legs, long necks, big heads), yet none of them were closely related. They also share the trait of being giant, flightless birds with vestigial wings, long legs, and long necks with the ratites, although they are not related. Certain longclaws (Macronyx) and meadowlarks (Sturnella) have essentially the same striking plumage pattern. The former inhabit Africa and the latter the Americas, and they belong to different lineages of Passerida. While they are ecologically quite similar, no satisfying explanation exists for the convergent plumage; it is best explained by sheer chance. Resemblances between swifts and swallows is due to convergent evolution. The chimney swift was originally identified as chimney swallow (Hirundo pelagica) by Carl Linnaeus in 1758, before being moved to the swift genus Chaetura by James Francis Stephens in 1825.
The number of COVID-19 hospital cases in Scotland have surpassed the previous winter's peak, data shows, with 448 people in hospital with the disease in the week ending 30 June, an increase on the previous week, and above the winter peak of 388. A team looking into how the Cass Review could apply to Scotland's health services for children and young adults recommends the Scottish Government pause the use of puberty blockers until further research into them is conducted. 7 July – Keir Starmer makes his first visit to Scotland as prime minister, for a meeting with First Minister John Swinney. 9 July – In an open letter to SNP members following the party's defeat in Scotland, former deputy leader Jim Sillars has described John Swinney's leadership as "a busted flush" and Nicola Sturgeon as "Stalin's wee sister". Brian Boyd, the Provost of Angus, resigns after berating a female councillor to the point of tears at an open council meeting. 11 July – The SNP confirms it will have to make the majority of its Westminster staff redundant after Parliament reduces its "Short Money" – the annual amount paid to opposition parties – by £1m. Data from Public Health Scotland indicates there were 49 COVID-related deaths in the week ending 1 July, with numbers having increased on previous weeks, while data obtained by BBC News indicates that as many as 260,000 people in at risk groups had not received a booster vaccine during the Spring 2024 programme when it ended on 30 June.
== Terminology == There exists some controversy about what structures are considered "fascia" and how they should be classified. The current version of the International Federation of Associations of Anatomists divides into:
In 2022 the National Institute for Health and Care Research (NIHR) published a comprehensive review of research on what local authorities can do to reduce obesity. The Obesity Policy Action (OPA) framework divides measure into upstream policies, midstream policies, and downstream policies. Upstream policies have to do with changing society, while midstream policies try to alter behaviors believed to contribute to obesity at the individual level, while downstream policies treat currently obese people.
Tadeusz Reichstein, Edward Calvin Kendall, and Philip Showalter Hench were awarded the Nobel Prize for Physiology and Medicine in 1950 for their work on hormones of the adrenal cortex, which culminated in the isolation of cortisone. Initially hailed as a miracle cure and liberally prescribed during the 1950s, steroid treatment brought about adverse events of such a magnitude that the next major category of anti-inflammatory drugs, the nonsteroidal anti-inflammatory drugs (NSAIDs), was so named in order to demarcate from the opprobrium. Lewis Sarett of Merck & Co. was the first to synthesize cortisone, using a 36-step process that started with deoxycholic acid, which was extracted from ox bile. The low efficiency of converting deoxycholic acid into cortisone led to a cost of US$200 per gram in 1947. Russell Marker, at Syntex, discovered a much cheaper and more convenient starting material, diosgenin from wild Mexican yams. His conversion of diosgenin into progesterone by a four-step process now known as Marker degradation was an important step in mass production of all steroidal hormones, including cortisone and chemicals used in hormonal contraception. In 1952, D.H. Peterson and H.C. Murray of Upjohn developed a process that used Rhizopus mold to oxidize progesterone into a compound that was readily converted to cortisone. The ability to cheaply synthesize large quantities of cortisone from the diosgenin in yams resulted in a rapid drop in price to US$6 per gram, falling to $0.46 per gram by 1980. Percy Julian's research also aided progress in the field.
Sources: en.wikipedia.org
Bud stage Cap stage Bell stage Crown stage The first sign of tooth development is known to be as early as the 6th week of intrauterine life. The oral epithelium begins to multiply and invaginates into ectomesenchyme cells, which gives rise to dental lamina. The dental lamina is the origin of the tooth bud. The bud stage progresses to the cap stage when the epithelium forms the enamel organ. The ectomesenchyme cells condense further and become dental papilla. Together the epithelial enamel organ and ectomesenchymal dental papilla and follicle form the tooth germ. The dental papilla is the origin of dental pulp. Cells at the periphery of the dental papilla undergo cell division and differentiation to become odontoblasts. Pulpoblasts form in the middle of the pulp. This completes the formation of the pulp. The dental pulp is essentially a mature dental papilla. The development of dental pulp can also be split into two stages: coronal pulp development (near the crown of the tooth) and root pulp development (apex of the tooth). The pulp develops in four regions from the periphery to the central pulp:
Ovothiol A (N1-methyl-4-mercaptohistidine) is a highly reducing antioxidant which accumulates to very high levels in the eggs of certain marine invertebrates, including sea urchins, scallops and starfish, where it acts to quench the hydrogen peroxide released during fertilization. This thiol-type antioxidant is also found in some human pathogens such as Trypanosoma cruzi and Leishmania donovani. It is synthesized by the addition and oxidation of cysteine to histidine by 5-histidylcysteine sulfoxide synthase, followed by methylation and further reduction.
If Carcass wasn't killed and Simon didn't give the gun to the doctor, he kills Sophie, his therapist, and then himself. He leaves a suicide note stating that he would have killed more people if it weren't for his disability and wishes that the people who find his body are haunted by it for the rest of their life. If Carcass wasn't killed and Simon gave the gun to the doctor, he kills Sophie, then himself. In his suicide note, he apologizes to his therapist and thanks him for his help, explaining that he killed Sophie so that he could have her all to himself since he never got over her rejection. If Carcass was killed and Simon didn't give the gun to the doctor, he kills his doctor, then himself. In his suicide note, he states that the doctor's therapy only made things worse, and begs for Sophie not to know what he's done. If Carcass was killed and Simon gave the gun to the doctor, Simon, right before he kills himself, is confronted by Book Simon. The player, taking control of the real Simon, chases down and kills Book Simon in a shootout. Coming to his senses, Simon realizes he had a mental episode. Instead of taking his own life, he killed two police officers who were presumably checking in on him. Simon gets admitted into a mental hospital for the rest of his life, where his therapist continues to look after him. Sophie, despite how much Simon hurt her, visits him. Hopeful about the future and finally at peace with his demons, Simon finishes his book.
Although the receptors for systemins and HypSys remain poorly understood, we have a better understanding of the signal transduction that occurs once the peptide had bound to its receptor. Jasmonic acid is an essential, albeit late component, in the systemin and wound-signalling pathways. In tomato, the signal is transduced from the receptor by mitogen-activated protein kinases (MAPKs). Cosilencing of two MAPKs, MPK1 and MPK2, in tomato compromised their defence response against insect larvae compared to wild type plants. Cosilencing these genes also decreased production of jasmonic acid and of jasmonic acid-dependent defence genes. Applying methyl jasmonate to cosilenced plants rescued them, indicating that jasmonates are the signal responsible for causing changes in gene expression. The alkalisation of the apoplast is a downstream effect of signalling processing by MAPKs. Applying fusicoccin, which activates the H+ ATPase inhibited by systemin, along with systemin still activates MAPKs, even though the pH of the apoplast does not change. Within minutes of systemin perception, the cytosolic Ca2+ concentration increases, and linolenic acid is released from cell membranes after a phospholipase has been activated. Linolenic acid is then converted to jasmonic acid via the octadecanoid pathway and jasmonic acid activates defensive genes. Production of methyl jasmonate is induced by systemins and also upregulates systemin precursor genes creating a feedback loop, amplifying the defensive signal.
Coconut milk powder is a fine, white powder used in Southeast Asian and other cuisines. Coconut milk powder is manufactured through the spray drying process of raw unsweetened coconut cream and is reconstituted with water for use in recipes that call for coconut milk. Many commercially available coconut milk powders list milk or casein among their ingredients. Some coconut milk powder formulations may have added ingredients such as maltodextrin, sodium caseinate, or trisodium phosphate.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.